Navigation Links
AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
Date:2/3/2011

ts to differ include the occurrence of adverse safety events with NUEDEXTA, that NUEDEXTA may not gain acceptance by the medical field, our dependence on third parties for manufacturing and distribution of NUEDEXTA, that we may not adequately build or maintain the necessary sales, marketing, supply chain management and reimbursement capabilities on our own or enter into arrangements with third parties to perform these functions in a timely manner or on acceptable terms, and other risks that are described in further detail in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to time in other publicly available information regarding the Company. Copies of this information are available from us upon request. We disclaim any intent to update these forward-looking statements.

All numbers disclosed in this press release are approximate.

AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.

©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 E-QURE, ... corporation engaged in the development and commercialization of its ... novel electrotherapy for the noninvasive treatment of hard to ... 2015, Zacks Small Cap Research http://scr.zacks.com issued ... . According to Zacks, research update, E-QURE Corp "…has ...
(Date:5/27/2015)... SAN JOSE, Calif. , May ... Inc. (NASDAQ: MXIM ) makes ... medical sensor and to monitor or ... with the DS28E80 gamma-radiation-resistant, nonvolatile (NV) ... Details for DS28E80: http://www.maximintegrated.com/en/products/digital/memory-products/DS28E80.html ...
(Date:5/27/2015)... 27, 2015  Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased ... and Chief Financial Officer, will present at the Jefferies 2015 ... EDT in New York City . ... accessed from the Cambrex website at www.cambrex.com in ... will be available for 90 days after the live event ...
Breaking Medicine Technology:Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 2Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE 3Gamma-Radiation-Resistant Memory Provides Calibration and Protects from Unsanitary Reuse in Medical Disposables 2Gamma-Radiation-Resistant Memory Provides Calibration and Protects from Unsanitary Reuse in Medical Disposables 3
... Dec. 1 CCS Medical, Inc. a leading direct-to-consumer provider ... from the United States Bankruptcy Court for District of Delaware ... marketing and proposed sale of substantially all of its assets. ... Court approved bidding procedures for the sale of substantially all ...
... , VIENNA, Va., Dec. 1 CEL-SCI Corporation (NYSE Amex: ... of vaccines and therapeutics for the prevention and treatment of ... of an international Contract Research Organization (CRO) to run CEL-SCI,s ... neck cancer with the Company,s lead product candidate, Multikine®. ...
Cached Medicine Technology:CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3
(Date:5/27/2015)... Stamford, CT (PRWEB) May 27, 2015 ... Skin Institute based in Stamford, CT has been selected ... of the first physicians nationwide (and the only physician ... injectable which allows for the removal of submental ... little to no recovery time, no surgery and minimal ...
(Date:5/27/2015)... In support of a new study ... Journal of American Geriatrics Society about the link between ... Commons OB-GYN P.A . is reiterating the nutritional value ... , To examine the relationship between diet soda intake ... Study of Aging (SALSA) tracked the soda consumption of ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 ... the first healthcare provider along the Gulf Coast ... management (CCM). In partnership with MD Revolution, a ... a new program that enables healthcare providers to ... reimbursements. This new, user-friendly program is designed to ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 ... of its SonarMD Platform, a first-of-its kind, ... and managing patients with chronic gastrointestinal disease. ... MD, MBA, the application allows physicians to ... through the ongoing use of electronic health ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... to Meet with,Members of Congress This Week, ... community-based Hispanic health organizations will converge on,Capitol Hill ... of President,George W. Bush,s veto of the bill ... Program (SCHIP)., The visits are part of ...
... Historic Accord Follows More Than a Year of Bargaining, ... at 14,California hospitals from Palm Springs to San Ramon ... Tenet Healthcare Corp., which was tentatively,agreed to by both ... If ratified, the agreement between Tenet and SEIU locals ...
... WYE ),confirmed today that it will appeal the ... in the Second Judicial District Court in Reno,Nevada, beginning ... presided over the trial. "This flawed verdict is ... V. Stein, Wyeth,s Senior Vice President and General Counsel.,"The ...
... Mugs in Charity Auction, TULSA, Okla., Oct. 15 ... get an autograph from your favorite celebrity, only to ... today,the first-annual celebrity autographed coffee mug auction; 100 percent ... for the Cure, the leader of,the breast cancer movement. ...
... Up With Jenesse Center Inc. for Complimentary Services and ... Month, LOS ANGELES, Oct. 15 Westside Medical Spa ... at renewing the,confidence of women preparing to embark on a ... victims of physical abuse, "Face the,Day" has partnered with Jenesse ...
... Company Prices New HIV/AIDS Salvage Drug at $9,900 ... Isentress, Merck,s New Integrase,Inhibitor. AHF Decries Overall Price ... Pharmaceutical Industry in Pricing, LOS ANGELES, Oct. ... and Co. Pharmaceuticals, for the,announced price for its ...
Cached Medicine News:Health News:National Alliance for Hispanic Health Ramps Up Lobbying for SCHIP Veto Override 2Health News:SEIU Locals, Tenet Reach Tentative Agreement 2Health News:Wyeth to Appeal Nevada Hormone Therapy Trial Verdict 2Health News:Wyeth to Appeal Nevada Hormone Therapy Trial Verdict 3Health News:Nonni's Biscotti Partners With Celebrities to Raise Funds for Breast Cancer Research 2Health News:Nonni's Biscotti Partners With Celebrities to Raise Funds for Breast Cancer Research 3Health News:Westside Medical Spa Launches 'Face the Day' to Aid Battered Women 2Health News:AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: